Xencor, Inc. $XNCR Stake Boosted by Trexquant Investment LP

Key Points

• Trexquant Investment LP increased its holdings in Xencor by 60.2%, acquiring an additional 50,119 shares during the first quarter, bringing their total to 133,360 shares worth approximately $1.42 million.
• Company insiders, including Director Richard J. Ranieri, sold 11,194 shares in the last ninety days, reflecting a decrease in their ownership but insiders still hold 4.76% of the company's stock.
• Xencor's stock price recently rose 2.2%, with a market capitalization of $609.79 million, while the company reported an 82.4% increase in revenue year-over-year for the recent quarter.

Trexquant Investment LP raised its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 60.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 133,360 shares of the biopharmaceutical company's stock after purchasing an additional 50,119 shares during the period. Trexquant Investment LP owned about 0.19% of Xencor worth $1,419,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Principal Financial Group Inc. increased its stake in shares of Xencor by 2.5% during the 1st quarter. Principal Financial Group Inc. now owns 348,726 shares of the biopharmaceutical company's stock valued at $3,710,000 after acquiring an additional 8,581 shares during the last quarter. Invesco Ltd. increased its stake in shares of Xencor by 44.3% during the 1st quarter. Invesco Ltd. now owns 656,201 shares of the biopharmaceutical company's stock valued at $6,982,000 after acquiring an additional 201,456 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Xencor by 53.1% during the 4th quarter. Deutsche Bank AG now owns 58,041 shares of the biopharmaceutical company's stock valued at $1,334,000 after acquiring an additional 20,128 shares during the last quarter. Northern Trust Corp increased its stake in shares of Xencor by 19.3% during the 4th quarter. Northern Trust Corp now owns 747,152 shares of the biopharmaceutical company's stock valued at $17,170,000 after acquiring an additional 120,655 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Xencor during the 4th quarter valued at about $632,000.

Analyst Ratings Changes

XNCR has been the subject of a number of research analyst reports. Wells Fargo & Company dropped their price objective on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Royal Bank Of Canada dropped their price objective on shares of Xencor from $32.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, August 21st. Bank of America downgraded shares of Xencor from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $23.00 to $12.00 in a research report on Wednesday, September 3rd. Finally, Wedbush reissued an "outperform" rating and set a $26.00 target price on shares of Xencor in a research report on Tuesday, September 2nd. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $22.25.

Xencor Price Performance

NASDAQ XNCR traded up $0.10 on Wednesday, reaching $8.41. The company had a trading volume of 282,393 shares, compared to its average volume of 760,846. The firm has a market capitalization of $599.83 million, a PE ratio of -3.50 and a beta of 0.82. Xencor, Inc. has a 1 year low of $6.92 and a 1 year high of $27.24. The firm has a 50-day moving average of $8.31 and a 200-day moving average of $9.49.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.78) by $0.37. The firm had revenue of $43.61 million during the quarter, compared to analysts' expectations of $22.59 million. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.Xencor's quarterly revenue was up 82.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.07) EPS. As a group, sell-side analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Kurt A. Gustafson sold 2,993 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the transaction, the director directly owned 20,183 shares in the company, valued at approximately $186,087.26. This represents a 12.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard J. Ranieri sold 2,993 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the transaction, the director owned 19,183 shares of the company's stock, valued at approximately $176,867.26. This trade represents a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,194 shares of company stock worth $103,209 in the last 90 days. 5.23% of the stock is owned by company insiders.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.